Vanco (bortezomib) is a first-line drug for the treatment of myeloma in Europe and the United States, with a unique mechanism of innovative targeted therapy. It is the world’s first synthetic proteasome inhibitor that delays, stops and treats multiple myeloma. Because its inhibition of the proteasome is reversible, it has a better safety profile for patients. In its 17-year history, VANCOUVER was first discovered by scientists at MYOGENICS, Inc. in the United States in 1995 and sponsored by the National Cancer Institute under the code name PS-341. The mechanism involved is the inhibition of the proteasome, which in turn interferes with the inhibition of the transcription factor NF-341 that helps tumor cell DNA to (This factor plays an important role in tumor cells in helping tumor angiogenesis, tumor cell replication, etc.) Interfering with NF-kB activation also directly or indirectly contributes to tumor cell death. In 1999, MYOGENICS was bought by LEUKOSITE due to a shortage of funds for research and development. Subsequently, LEUKOSITE was bought by Millennium Pharmaceuticals, Inc. due to the shortage of funds due to the large amount of money invested in research and development. Just like that, the research and development of VANCOUVER, the two companies have disappeared since then. Subsequently, Millennium decided to continue the development of PS-341 (also known as VANCOUVER) in collaboration with Johnson & Johnson in the United States, considering the overwhelming amount of money invested in research and development. The first clinical subjects treated with Vanko for multiple myeloma reached a state of complete recovery (not a complete cure of the disease here, but a state of very good control of the disease, sCR, or complete remission, essentially indistinguishable from normal people) and were still alive four years later. This exciting result brought Vanco to the middle of the myeloma treatment stage. Subsequent clinical studies have shown that 35% of a group of myeloma patients who did not respond to treatment or who had relapsed, responded to treatment with Vanco, and 10% of these patients were in complete or near complete remission (sCR or CR, very effective). Such a response rate is highly significant, as it is quite rare for patients with late-stage disease or myeloma patients who do not respond to other treatments to have a complete remission. Given the evidence from two clinical trials that PS-341 (Vanco) did have a sustained efficacy response, it prompted the U.S. Food and Drug Administration (FDA) to fast-track its review and approval for the treatment of multiple myeloma in May 2003. With the launch of VANCOUVER, patients with multiple myeloma undoubtedly see a new hope to extend their lives and improve their quality of life. Although the price of Vancor is currently high in China because it is not covered by medical insurance, life is priceless. However, life is priceless, and it is the most important thing for doctors to treat patients with the best medicine. In my clinical practice, I often treat myeloma patients with multiple chemotherapy regimens, and some of them are unable to use Vanco for financial reasons, resulting in poor outcomes. I also hope that Vanco, a first-line drug for myeloma that is covered by health insurance in Europe and the United States, will soon enter the Chinese health insurance list, so that I can see more myeloma patients in remission and their smiles of relief.